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Abstract 1 
 2 
The association of antipsychotic medication with abnormal brain morphometry in 3 
schizophrenia remains uncertain. This study investigated subcortical morphometric changes 4 
6 months after switching treatment to clozapine in patients with treatment-resistant 5 
schizophrenia compared with healthy volunteers, and the relationships between longitudinal 6 
volume changes and clinical variables. 1.5T MRI images were acquired at baseline before 7 
commencing clozapine and again after 6 months of treatment for 33 patients with treatment 8 
resistant schizophrenia and 31 controls, and processed using the longitudinal pipeline of 9 
Freesurfer v.5.3.0. Two-way repeated MANCOVA was used to assess group differences in 10 
subcortical volumes over time and partial correlations to determine association with clinical 11 
variables. Whereas no significant subcortical volume differences were found between 12 
patients and controls at baseline(F(8,52)=1.79; p= 0.101), there was a significant interaction 13 
between time, group and structure(F(7,143)=52.54, p<0.001). Corrected post-hoc analyses 14 
demonstrated that patients had significant enlargement of lateral ventricles (F(1,59)=48.89; 15 
p<0.001) and reduction of thalamus (F(1,59)=34.85; p<0.001), caudate (F(1,59)=59.35; 16 
p<0.001), putamen (F(1,59)=87.20; p<0.001) and hippocampus (F(1,59)=14.49; p<0.001) 17 
volumes. Thalamus and putamen volume reduction was associated with improvement in 18 
PANSS (r=0.42; p=0.021, r=0.39; p=0.033), SANS (r=0.36; p=0.049, r=0.40; p=0.027) and GAF 19 
(r=-0.39; p=0.038, r=-0.42; p=0.024) scores. Reduced thalamic volume over time was 20 
associated with increased serum clozapine level at follow-up (r=-0.44; p=0.010). Patients with 21 
treatment-resistant schizophrenia display progressive subcortical volume deficits after 22 
switching to clozapine despite experiencing symptomatic improvement. Thalamo-striatal 23 
progressive volumetric deficit associated with symptomatic improvement after clozapine 24 
exposure may reflect an adaptive response related to improved outcome rather than a 25 
harmful process. 26 
 27 
 28 
 29 
 30 
 31 
 32 
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1. Introduction  33 
 34 
Approximately 30% of patients with schizophrenia meet criteria to be considered treatment-35 
resistant[1,2], usually defined as the failure to respond to at least two adequate trials of 36 
antipsychotic medication[3]. Clozapine has an established superior clinical effect to control 37 
symptoms in treatment-resistant patients, with 60-70% having a positive response[4,5]. 38 
Patients treated with clozapine also often experience troublesome side effects including 39 
significant weight gain and lipid abnormalities[6], which notably have been associated with 40 
improvement in symptomatology[7,8]. Cross-sectional MRI studies of patients with treatment 41 
resistant schizophrenia (TRS) receiving clozapine and other antipsychotic medications have 42 
reported a range of brain abnormalities compared with controls, including reduced global 43 
grey matter[9,10], predominantly in frontal and temporal regions[11–13], and volumetric 44 
reduction of the amygdala and hippocampus[12,13]. 45 
  The association of antipsychotic medication use with progressive brain deficits has 46 
been explored in longitudinal studies of schizophrenia[14,15]. These studies mostly use an 47 
observational rather than randomised design approach and thus cannot fully account for 48 
illness or service-related factors which influence clinician and patient medication choice. In a 49 
meta-analysis of longitudinal MRI studies based on 1155 patients with schizophrenia and 911 50 
healthy controls, Vita and colleagues[15] reported reduced cortical grey matter volume over 51 
time in patients which was related to cumulative exposure and mean daily dose of 52 
antipsychotic medications. Patients treated with first-generation antipsychotic (FGA) 53 
medications compared to second-generation antipsychotics (SGA) displayed more 54 
progressive grey matter loss, which correlated with higher mean daily antipsychotic dose. 55 
Likewise, van Haren and colleagues’[16] 5-year longitudinal study reported an association 56 
between higher cumulative dose of FGA over time and more marked cortical thinning, while 57 
higher dose of SGA in contrast was associated with less cortical thinning. However, patients 58 
who received clozapine treatment during the interscan interval showed more pronounced 59 
superior temporal cortical thinning compared with those not treated with clozapine. In 60 
contrast, in another analysis of this cohort, higher cumulative dose of clozapine during the 61 
interscan interval was related to attenuated loss of grey matter in the left superior frontal 62 
gyrus[17].  63 
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Longitudinal subcortical neuroimaging studies specifically of treatment-resistant 64 
clozapine-naïve patients are sparse, with small numbers of participants or without a matched 65 
control group. An early study of subcortical structures by Chakos and colleagues[18] based on 66 
15 patients, and without a control group, reported a 10% decrease in caudate volume after 67 
55 weeks, when switched from treatment with typical antipsychotic medications to clozapine. 68 
In contrast, patients who stayed on typical antipsychotic medications displayed an 8% 69 
enlargement in the caudate. In another study of 26 patients by Scheepers and colleagues[19] 70 
volume reduction of caudate nucleus was identified after 24 weeks of treatment with 71 
clozapine. There was no neuroanatomical correlation with clinical response. In the same 72 
cohort, after 52 weeks of treatment, reduced volume of the left caudate was greater in 73 
patients who responded to treatment compared to non-responders[20]. Another small study 74 
with 8 patients and 8 controls reported reduced caudate volume after 2 years of treatment 75 
with clozapine, with analogous results for the putamen, which was not statistically 76 
significant[21]. Thus, these early studies consistently indicate that switching patients from 77 
FGA medication to clozapine is associated with a decrease of caudate volume over time, and 78 
has generally been interpreted as a correction by clozapine of caudate hypertrophy induced 79 
by FGA medication due to their potent dopamine blockade and the high concentration of 80 
dopamine receptors in the caudate[22]. However, nowadays most patients are already taking 81 
SGA medications prior to clozapine commencement and it remains unclear whether switching 82 
to clozapine in such circumstances would have a similar effect on the basal ganglia. 83 
Furthermore, other subcortical structures such as the hippocampus and thalamus have not 84 
been investigated in longitudinal studies of switching to clozapine. 85 
Given the importance of identifying factors predicting response to clozapine, the 86 
association of clinical response with baseline alterations in subcortical structures has also 87 
been studied, with conflicting results. In a randomised controlled trial by Arango and 88 
colleagues[23], whereas larger right prefrontal cortex predicted improvement in SANS scores 89 
compared with haloperidol treated patients, there was no such association between clinical 90 
symptom change and caudate or hippocampal volume at baseline. Smaller hippocampal 91 
volume compared to healthy controls at baseline predicted improvement in disorganised 92 
symptoms over time in a longitudinal study by Molina and colleagues[24]. In another 93 
longitudinal study, decreased left caudate volume over time was related to a significant 94 
improvements in positive and general symptoms, but not negative symptoms[20].   95 
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We have previously investigated cortical anatomy in a sample of patients before and 96 
after switching to clozapine in comparison to healthy volunteers[25], and demonstrated on-97 
going cortical thinning in TRS patients over a 6 month period, in particular for younger 98 
patients.  The present study, using a unique sample of treatment-resistant clozapine-naïve 99 
schizophrenia patients, offers a novel opportunity to comprehensively investigate whether 100 
subcortical structures demonstrate progressive neuroanatomical changes after 6 months of 101 
clozapine treatment and whether any such changes are related to clinical variables including 102 
treatment response and amount of clozapine taken.  103 
 104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
  125 
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2. Method 126 
2.1 Participants 127 
As previously reported[25] 39 patients with treatment-resistant schizophrenia (TRS) prior to 128 
clozapine initiation and 40 healthy volunteers (HC) were initially recruited for the baseline 129 
assessment. At the follow-up, 33 patients, after 6 months of treatment with clozapine and a 130 
total of 31 healthy controls, matched for sex and age, were successfully re-recruited, scanned 131 
and assessed (Table 1). Patients were included if aged 18-60 years and clinically due to switch 132 
to clozapine because of treatment resistance. Patients and controls were excluded from the 133 
study if they had a previous trial of clozapine treatment, a learning disability, history of 134 
neurological illness, history of head injury which resulted in loss of consciousness for over 5 135 
minutes, treatment with oral steroid in the three months prior to participation, history of 136 
comorbid alcohol/ substance dependency as defined by the DSM-IV criteria or any 137 
contraindication to MRI scanning. Exclusion criteria for controls also included a current or past 138 
axis I mental disorder or any psychotic disorder in a first-degree relative. The study was 139 
approved by the Clinical Research Ethics Committee, Galway University Hospitals. Fully 140 
informed written consent was obtained for all participants. 141 
2.2 Clinical assessment 142 
All patients were diagnosed using the Diagnostic and Statistical Manual for Mental Disorders 143 
4th Edition text revision (DSM-IV-TR) (American Psychiatric Association, 2000). Treatment 144 
resistance was defined as the failure to respond to at least two adequate trials of 145 
antipsychotic medications, including at least one atypical antipsychotic drug, with a prolonged 146 
period of moderate to severe positive and/or negative symptoms[26]. The severity of positive 147 
and negative symptoms was assessed at both time points using the Positive and Negative 148 
Syndrome Scale (PANSS)[27], the Scale for the Assessment of Positive Symptoms (SAPS)[28] 149 
and the Scale for the Assessment of Negative Symptoms (SANS)[29]. Social, occupational and 150 
psychological functioning was assessed using a Global Assessment of Functioning Score[30]. 151 
We used the symptomatic remission criteria of Andreasen[31] with the exclusion of the 152 
maintenance over 6-month observation period[32]. Remission at the 6 month follow-up 153 
assessment was therefore defined as having scores of mild or less (item scores of ≤2 using the 154 
0-6 range) on all eight of the following PANSS items: delusions (P1), conceptual 155 
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disorganisation (P2), hallucinatory behaviour (P3), blunted affect (N1), social withdrawal (N4), 156 
lack of spontaneity (N6), mannerisms / posturing (G5), unusual thought content (G9).  157 
 2.3 MRI data acquisition 158 
MRI images were acquired for all participants at baseline and after 6 months at University 159 
Hospital Galway in a 1.5 Tesla Siemens Magnetom Symphony scanner (Erlangen, Germany) 160 
equipped with a 4-channel head coil. A magnetisation prepared rapid gradient echo 161 
(MPRAGE) sequence was acquired to generate high resolution volumetric T1-weighted 162 
images, with the following parameters: repetition time (TR): 1140 ms, echo time (TE): 4.38 163 
ms, inversion time (TI): 600 ms, flip angle: 15°, matrix size: 256x256, interpolated to 512 x 164 
512, slice thickness: 0.9 mm and in-pixel resolution: 0.45 mm2 165 
2.4 MRI processing 166 
Volumetric T1-weighted images used in the analyses were intensity inhomogeneity corrected 167 
using non-parametric, non-uniform intensity normalisation (N3)[33] as previously 168 
reported[25,34]. Eight subcortical regions-of-interest: lateral ventricle, thalamus, 169 
hippocampus, caudate, putamen, globus pallidus, amygdala and nucleus accumbens, were 170 
bilaterally segmented using the longitudinal pipeline of Freesurfer v.5.3.0[35,36]. Specifically, 171 
this technique is based on an unbiased within-subject anatomical template[35], created using 172 
a robust and inverse consistent registration method[37], is able to overcome the limitations 173 
of longitudinal processing methods. It reduces the risk of underestimating change, giving an 174 
unbiased estimation of the neuroanatomical structure volume over time, removing 175 
asymmetry-induced processing bias and avoiding over-regularization or temporal 176 
smoothness constraints[35]. This technique has also sufficient sensitivity and reliability for 177 
small sample sizes[35]. The several steps of the processing pipeline to obtain the output have 178 
previously been described in detail[38]. Intracranial volume (ICV), is computed by dividing a 179 
predetermined constant with the factor by which the input magnetic resonance (MR) images 180 
are scaled in size to align to the MNI305 head atlas[39–41]. At each time point, quality check  181 
of the segmentation output was performed, which involves a visual inspection at each of the 182 
analysis stages, to verify that the segmentation was anatomically accurate and 183 
computationally successful[42]. Six images failed the quality check and required manual 184 
editing using control points to fix intensity normalization[43]. Following quality check and 185 
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manual editing, no images were excluded. Subsequently subcortical volumes were bilaterally 186 
extracted and summed together to obtain one measure for each ROI. 187 
2.5 Statistical analysis    188 
Statistical Package for the Social Sciences version (SPSS Inc., v23, IBM, New York, USA) was 189 
used to carry out all analyses. The Shapiro-Wilks Test was used to test for normal distribution 190 
of demographics, clinical, neuroanatomical and anthropomorphic variables, with outliers 191 
defined as greater or less than 3 standard deviations from the mean. Age, gender and time 192 
between scanning were compared between groups using either a T-test, Chi-square or Mann-193 
Whitney U Test. Differences between baseline and follow-up on clinical variables and 194 
anthropomorphic measurements were tested using the Wilcoxon Signed Ranks and Paired-195 
Sample T-test. An initial one-way Multivariate analysis of covariance (MANCOVA) was 196 
performed to evaluate differences between groups at baseline on the eight subcortical 197 
structures, covarying for age, sex and ICV. Post-hoc analyses were performed to assess 198 
differences at baseline on the 8 subcortical structures between controls and patients 199 
previously treated with atypical and/or typical medications. Thereafter two-way repeated 200 
MANCOVA was used to assess the course of changes in volume of subcortical structures over 201 
time between groups, covarying for age, sex and ICV. The group-by-age interaction was used 202 
to determine the effect of age on anatomical change between groups over time. Post-hoc 203 
analysis, corrected for multiple comparison (Bonferroni, α= 0.006) was carried out to clarify 204 
which regions were significantly changing over time. An additional one-way MANCOVA and 205 
subsequently a two-way repeated MANCOVA was performed to assess differences between 206 
clozapine responders and non-responders at baseline and over time on subcortical structures, 207 
covarying for age, sex and ICV. Partial correlations were carried out controlling for the 208 
potential influence of age, sex and ICV on the relationship between the subcortical brain 209 
regions which showed a significant change over time (
𝐹𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒  
𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒
× 100)  and 210 
change in PANSS, SANS, SAPS and GAF (Follow-up−Baseline)[10]. These correlations were 211 
hypothesis driven and not corrected for multiple comparison. Pearson correlation analyses 212 
were performed to explore the relationship between subcortical structures showing a 213 
significant change over time in TRS patients and the variables age, duration of illness, body 214 
mass index (BMI), daily dose and serum level of clozapine at follow-up. 215 
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3. Results 216 
3.1 Clinical characteristics 217 
Patient and control groups did not differ across age, sex, and time between scans (Table 1). 218 
Patients after treatment with clozapine displayed a substantial and statistically significant 219 
improvement in each symptom and function rating scale. At follow-up, patients also displayed 220 
a significant increase of weight, waist, body mass index, total cholesterol and triglycerides 221 
compared to baseline (Table 2). Twelve patients had previously been prescribed typical 222 
antipsychotic drugs and 5 were still taking FGA medications at the point of the baseline scan. 223 
At baseline before switching to clozapine, 21 patients were on monotherapy with one SGA 224 
medication (olanzapine=7, quetiapine=4, aripiprazole=4, amisulpiride=1, paliperidone=1, 225 
risperidone long acting injection=1), 10 patients were treated with two antipsychotic 226 
medications (olanzapine + another antipsychotic=7), with one patient treated with three and 227 
another patient treated with four antipsychotic medications. At follow-up 16 patients (48%) 228 
were in remission. 229 
3.2 Differences between groups on subcortical regions at baseline and over time 230 
There was no significant difference between TRS patients and controls at baseline (n=33 TRS; 231 
n=31 HC) when considering jointly the 8 subcortical structures and taking account of multiple 232 
comparisons (F(8,52)= 1.79; p= 0.101, Table 3). We also assessed for differences in subcortical 233 
structures at baseline in the larger initially recruited sample (n=39 TRS; n=40 HC). Volumetric 234 
changes in structures such as hippocampus and lateral ventricles did not survive overall 235 
multiple comparison correction (F(8,66)=1.82; p= 0.088, Suppl. Table 1), but were in keeping 236 
with the effects sizes (circa 0.5) identified for such structures in larger case control samples 237 
of patients with schizophrenia[44]. However, a strong significant overall interaction between 238 
time, group and brain structure was demonstrated (F(7,143)= 52.54; p<0.001, Table 3). Post-239 
hoc analyses, robustly corrected for multiple comparison (Bonferroni, α=0.006), revealed a 240 
significant volumetric increase in lateral ventricle (F(1,59)=48.89; p<0.001, Figure 1A) and 241 
decrease in thalamus (F(1,59)=34.85; p<0.001, Figure 1B), caudate (F(1,59)=59.35; p<0.001, 242 
Figure 1C), putamen (F(1,59)=87.20; p<0.001, Figure 1D) and hippocampus (F(1,59)=14.49; 243 
p<0.001, Figure 1E) volumes for patients compared to healthy controls (Table 3). The relative 244 
consistency of the progressive volumetric changes in the patient cohort is apparent from the 245 
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individual level data points displayed in Supplementary Figure 1. There was no significant 246 
group-by-age interaction on the progression of the subcortical structures between patients 247 
and controls (F(84,112)= 1.13; p=0.272). Post-hoc analysis revealed no significant differences 248 
at baseline between controls and patients previously treated with atypical and/or typical 249 
medications when considering the 8 subcortical structures (F(8,16)=1.49; p= 0.117).  250 
3.3 Response to clozapine and subcortical changes at baseline and over time 251 
When investigating the baseline differences between those who remitted on clozapine 252 
treatment (n=16) and non-responders (n=17) for the 8 subcortical structures, no significant 253 
differences were revealed (F(8,21)=1.32; p=0.286). Likewise, there was no significant overall 254 
effect of time on subcortical brain structures between patients responding to clozapine 255 
compared to patients non-responders (F(7,20)=0.50; p=0.834).  256 
3.4 Correlation between neuroanatomy and clinical variables in treatment-resistant patients 257 
In TRS patients, when covarying for age, sex and ICV,  volumetric reduction of thalamus and 258 
putamen over time were significantly associated with improvement in PANSS Total score 259 
(r=0.42, p=0.021; r=0.39, p=0.033, respectively Figure 2A) and improvement in negative 260 
symptoms assessed with the SANS scale (r=0.36, p=0.049; r=0.40, p=0.027, respectively Figure 261 
2B). Similarly, improvement in PANSS General score was significantly related to decreased 262 
volume in thalamus over time (r=0.39; p=0.034). Controlling for serum clozapine level at 263 
follow-up and duration of illness did not impact on the above findings, however improvement 264 
of GAF was additionally found to relate to reduced thalamic (r=-0.39; p=0.038) and putaminal 265 
(r=-0.42; p=0.024) volume (Figure 2C). Improvement in SAPS was associated with reduced 266 
putaminal volume (r=0.39; p=0.035), but this association weakened slightly and lost 267 
significance (r=0.31; p= 0.102) when removing one outlier who demonstrated a 76% 268 
improvement in positive symptoms. No other associations were found between change in 269 
other subcortical brain structures and clinical variables (Suppl. Table 2). 270 
 271 
 272 
3.5 Exploratory analyses between structures showing significant change over time in patients 273 
and treatment-related factors.  274 
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When exploring the association between changes over time in subcortical structures and 275 
treatment related factors in patients, including BMI change, and serum clozapine at follow-276 
up, a significant association was identified between reduced volume of the thalamus over 277 
time and increased clozapine serum level at follow-up (r=-0.44; p=0.010, Figure 2D), with this 278 
correlation strengthening (r=-0.49; p=0.010) when controlling for change in clinical symptoms 279 
(PANSS, SAPS, SANS) and functioning (GAF). 280 
 281 
4. Discussion  282 
To the best of our knowledge, this is the largest sample to date to examine the effects of 283 
switching to clozapine on subcortical regions in a relatively clinically homogenous sample of 284 
TRS patients using a longitudinal semi-automated subject-specific approach (Freesurfer 285 
v.5.3.0)[36]. In this longitudinal study, minor subcortical differences were detected between 286 
patients and controls at baseline, which failed to survive multiple comparisons correction. 287 
However, we identified substantial progressive volumetric reduction of the thalamus, 288 
hippocampus, caudate, putamen and enlargement of lateral ventricles over a 6-month period 289 
in patients compared to controls. Reduced caudate volume over time has been consistently 290 
reported in the majority of studies of patients switched from typical antipsychotic 291 
medications to clozapine[18–21] and has been interpreted as reversal of previous 292 
enlargement due to excessive dopamine blockade. Consistent with this, longitudinal studies 293 
demonstrate basal ganglia enlargement when taking typical medications was reversed by 294 
switching to atypical antipsychotic medications[45,46]. Reduction of thalamic volume over 295 
time was also reported in a 5-year longitudinal voxel-based morphometry study[17]. 296 
However, no association has previously been reported between cumulative doses of 297 
clozapine and subcortical deficits. The hippocampal progressive reduction identified in this 298 
cohort on switching to clozapine has not been previously reported, but notably the direction 299 
of change is in keeping with the other subcortical structures. The lateral ventricle enlargement 300 
over time could be interpreted as ventricular expansion as a result of the significant reduction 301 
of surrounding subcortical regions[47]. The degree of volumetric change in this cohort after 6 302 
months in regions such as the hippocampus and lateral ventricles is comparable to the rate 303 
of change detected in previous longitudinal studies over longer time periods [48,49]. The high 304 
density of dopamine D2 receptors[50] in basal ganglia and other structures such as thalamus 305 
11 
 
and hippocampus, renders them major targets to which dopaminergic pathways project[51]. 306 
In a preclinical study, Guma and colleagues[52], presented evidence that D2 receptors play a 307 
significant role in mediating antipsychotic induced structural changes, whereby volumetric 308 
reduction in cortical areas, hippocampus and thalamus, was induced by genetic deletion of 309 
D2 receptors.  310 
Our study did not detect any difference in subcortical structures between those who 311 
achieved clinical remission with clozapine treatment and non-responders, either at baseline 312 
or over time, consistent with some previous studies[9,19]. In one longitudinal study of 313 
patients (which did not include a control sample), responders showed a significant reduction 314 
in left caudate volume after 24 weeks of clozapine treatment[20]. 315 
These results lead us to speculate on three reasons for the lack of significant baseline 316 
subcortical volume deficits in patients compared with controls in this cohort and the 317 
subsequent marked progressive volume loss over time after commencing clozapine. (i) Direct 318 
effects of clozapine treatment, (ii) withdrawal of prior treatment with other medications, or 319 
(iii) illness progression independent of medication use. 320 
 (i) This cohort of TRS patients may be a categorically different illness subtype with 321 
different underlying mechanisms and pathophysiology compared with D2 receptor antagonist 322 
responsive schizophrenia[53,54]. Lack of the striatal dopaminergic elevation in TRS, typical in 323 
schizophrenia could explain why treatment with dopamine antagonists are ineffective as they 324 
target the wrong processes[55]. Abnormal glutamatergic function, with higher glutamate + 325 
glutamine level concentrations have been reported in TRS compared to first-line 326 
responders[54,56]. Indeed it has been suggested that clozapine’s efficacy might relate to its 327 
ability to attenuate glutamate release, as demonstrated in preclinical studies[57]. In our 328 
cohort the previous lack of symptomatic response to typical and atypical antipsychotic 329 
medications may have related to relative subcortical volume preservation compared with 330 
healthy controls. Hence, the subcortical volume loss after commencing clozapine treatment 331 
may directly have been related to clozapine efficacy[19]. Indeed,  cross-sectional studies on 332 
neuroanatomy of TRS patients are usually on patients already receiving clozapine, and 333 
demonstrate reduction of cortical and subcortical volumes[9,12,13], as we see at the follow-334 
up point in our study when patients are on clozapine treatment. It may also be that acutely 335 
symptomatic phase of illness is linked to increased neuroinflammation which has been 336 
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associated with increases in local blood flow, vascular permeability, microglia activation and 337 
extracellular volume[58] . In this scenario, successful treatment with clozapine might have 338 
resulted in an anti-inflammatory process[59] that reversed these inflammatory changes, 339 
resulting in subcortical volume reduction. 340 
 (ii) Prior exposure of this cohort to antipsychotic medications over the years might 341 
have ameliorated or corrected disease-related volume loss[15,16,44,60], which may explain 342 
our finding of only minor baseline volume differences. Interestingly unmedicated patients 343 
have been reported to display greater subcortical deficits, especially of the caudate and 344 
thalamus, compared to medicated patients[44,61].  On this interpretation, the progressive 345 
brain volume change of subcortical structures on switching to clozapine treatment might have 346 
been related to the withdrawal of other atypical antipsychotic medications. The 347 
neurobiological mechanism that underlies the progressive volumetric loss of subcortical 348 
structures is still unknown, however neural apoptosis, necrosis, synaptic pruning might play 349 
a role in producing volume deficits[62].  350 
(iii) The progressive volume loss of subcortical structures in patients revealed by 351 
scanning over two time-points was not associated with pharmacotherapy, but rather to the 352 
underlying pathophysiology of this malignant form of schizophrenia illness and/or other 353 
illness-related factors which were not present in controls. However, this explanation seems 354 
unlikely since patients in our cohort have a mean illness duration of 13 years and only some 355 
were in the early stages of illness. 356 
The progressive loss of volume in subcortical structures despite symptomatic and functional 357 
improvement suggests that volume loss as detected by neuroimaging in vivo in our cohort 358 
should not be necessarily interpreted as harmful to patients. Although cognitive impairment 359 
has been related to cortical thinning or volume reduction in schizophrenia[63–65], grey 360 
matter loss has been associated with greater response to atypical antipsychotics[66,67]. 361 
Moreover, cortical thinning in first-episode schizophrenia patients on pharmacotherapy has 362 
been associated with physiological and cognitive improvement[68]. Consistent with this, 363 
progressive volumetric reduction of putamen and thalamus was significantly associated with 364 
better response to clozapine. This result was unaltered after controlling for the serum level 365 
of clozapine and duration of illness. Interestingly Scheepers and colleagues, reported an 366 
association between clinical improvement in positive and general symptoms and reduction of 367 
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left caudate volume, in TRS patients[20]. Molina and colleagues, in a 2 years randomised 368 
clinical trial of clozapine on 17 neuroleptic-naïve patients with schizophrenia and 11 controls, 369 
have shown that inferior frontal thinning, specifically, pars orbitalis, opercularis and 370 
triangularis, was positively associated with better clinical and cognitive response to clozapine 371 
[69].  372 
We also found that patients who were exposed to higher amounts of clozapine displayed a 373 
greater reduction of thalamus volume, this association was further reinforced when 374 
controlling for clinical symptoms and functioning, suggesting a direct effect of clozapine on 375 
the volumetric change of the thalamus.  Vita and colleagues’ meta-analysis described a 376 
consistent finding where the greater the exposure to antipsychotics the greater the reduction 377 
in grey matter volume[15]. Two longitudinal studies have shown that the amount of exposure 378 
to antipsychotics predicted reduction of caudate and grey matter volumes[14] and the 379 
greater progressive brain reduction and ventricular enlargement were predicted by greater 380 
exposure to antipsychotic medication[70]. Although these studies have been interpreted as 381 
consistent with a toxic effect of antipsychotic medication on grey matter, generally patients 382 
were not randomised in these longitudinal studies and it is likely that patients with more 383 
severe illness were given larger amounts of medication. In our study other variables, such as 384 
age, duration of illness and daily dose of clozapine were not significant moderators of 385 
subcortical volume change over time, as previously reported[15].  386 
A recent systematic review concludes that after 25 years of research it remains unclear which 387 
are the biological predictors of symptomatic response to clozapine [71]. Greater integrity and 388 
activity in prefrontal cortical areas associated with a good response to clozapine is the most 389 
consistent finding, however, studies have failed to find any accurate and reproducible 390 
neuroanatomical biomarker to inform clinical decision-making. Although our study identified 391 
a relationship between thalamo-striatal progression and clinical and functional improvement, 392 
we did not identify any baseline subcortical predictor of remission on clozapine.  393 
 394 
 395 
Strengths and limitations 396 
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The main strength of this study is the longitudinal nature of a relatively large and homogenous 397 
sample of TRS patients. The careful segmentation of the subcortical structures using the 398 
longitudinal stream of Freesurfer based on an unbiased within-subject anatomical 399 
template[35] enabled increased anatomical sensitivity to better detect anatomical changes 400 
and relationships to clinical symptoms and functioning. A potential limitation of this study is 401 
the lack of a comparative group of schizophrenia patients treated with other antipsychotic 402 
medications, in order to disentangle disease effects from treatment effects. However, such a 403 
comparative group may represent a less malign subgroup of patients with schizophrenia who 404 
are not treatment resistant and consequently may have a different underlying 405 
pathophysiology/impact of antipsychotic medication on their neuroanatomy.  Ultimately 406 
including MR imaging in longitudinal studies of schizophrenia where patients are randomised 407 
to different antipsychotic medications would be necessary to tease apart illness from 408 
treatment effects but only three such studies have been conducted to our 409 
knowledge[60,69,72] and none on patients with treatment resistance. In addition, to reduce 410 
multiple analyses we assessed only subcortical structures summed bilaterally and did not 411 
explore any lateralised effects. 412 
Conclusion 413 
This study demonstrates that, despite the clinical and functional improvement of most 414 
patients with schizophrenia who are switched to clozapine, there is a counterintuitive 415 
progressive volume reduction in several subcortical structures over time. Furthermore, 416 
patients who have the greatest symptomatic improvement display the largest thalamo-417 
striatal reductions, suggesting that volume reduction reflects an adaptive response associated 418 
with symptom improvement rather than a harmful process in these treatment resistant 419 
patients. Further longitudinal studies with larger sample size, randomised designs and 420 
multimodal imaging will be necessary to disentangle the potentially dynamic effects of 421 
neuroprogression and antipsychotic treatment on different brain structures in schizophrenia. 422 
 423 
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Figure Legends 664 
Figure 1 665 
(A,B,C,D,E) Plots of subcortical structures that presented significant changes over time in 666 
treatment-resistant schizophrenia patients compared to healthy controls. Note: all values 667 
corrected for age, sex and ICV.  668 
Figure 2 669 
Association between percentage of volume change in thalamus and putamen and change in 670 
(A) PANSS Total score (B) SANS (C) GAF and (D) association between percentage of volume 671 
change in thalamus and level of serum of clozapine at follow-up.  672 
Supplementary Figure 1 673 
Illustration of the change in lateral ventricles, thalamus, caudate and putamen volume from 674 
baseline to follow-up for each patient and healthy control. Red bars represent the mean.  675 
 676 
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 679 
 680 
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Table 1. Characteristics of patients with treatment resistant-schizophrenia and controls. 696 
  Patient group  
(n=33) 
Control group  
(n=31) 
Test statistic/p-value 
Sex (m/f) 23/10 20/11 X2= 0.19; 0.660 
Age at onset (years) 22.8 ± 0.8   
Age at baseline (years) 36.4 ± 10.7 39.3 ± 10.6 t= 1.10; 0.274 
Age range (22-61) (23-59)  
Time between baseline and 
follow-up MRI scans (months) 
6.6 ± 1.7 7.4 ±3.2 t= 1.21; 0.230 
Illness duration before 
commencing clozapine (years) 
13.6 ± 8.8   
Intracranial volume (mm3) 1610322.58 ± 
29886.83 
1591515.15 ± 
27500.42  
t= 0.46; 0.644 
 697 
 698 
Table 2. Clinical features of patient group at baseline and follow-up (n=33) 699 
 Baseline 
(Mean ± SD) 
Follow-up 
(Mean ± SD) 
Test statistic/ 
p-value 
    
Clinical scales     
  PANSS positive score 14.1 ± 5.7 6.1 ± 5.0 *z= -4.98; < 0.001 
  PANSS negative score 16.2 ± 7.0 9.1 ± 7.1 *z= -4.51; < 0.001 
  PANSS general score 24.1 ± 8.9 11.7 ± 8.3 *z= -4.90; < 0.001 
  PANSS Total Score 54.3 ± 17.8 26.9 ± 17.6 t= 10.04; < 0.001 
  SANS 42.5 ± 20.7 27.8 ± 22.9     *z=-3.78; < 0.001 
  SAPS 28.0 ± 16.3 13.2 ± 11.0 *z= -4.45; < 0.001 
  Global assessment of functioning 46.8 ± 10.8 64.9 ± 14.1    t= 13.12; < 0.001 
    
Medications    
  Typical antipsychotics (n) 5 0  
  Atypical antipsychotics (n) 33 2  
  Clozapine (n) 0 33  
  Serum level of clozapine at follow-
up (ng/ml) 
 0.5 ± 0.1  
  Daily dose of clozapine at follow-up 
(mg) 
 349.2 ± 17.8  
Daily dose of clozapine range (mg)  (200-625)  
Anthropomorphic measurements    
  Weight (kg) 85.9 ± 15.4 90.1 ± 16.6 t=-3.31; 0.002 
  Waist circumference (cm) 97.8 ± 12.1 103.1 ± 13.4 t=-4.94; < 0.001 
  Body Mass Index 28.0 ± 4.9 29.3 ± 5.0 *z= -2.78; 0.005 
  Total Cholesterol (mmol/L) 4.8 ± 1.1 5.5 ± 0.8 t=-3.38; 0.003 
  Triglycerides (mmol/L) 1.8 ± 1.0 2.5 ± 1.4      *z= -2.62; 0.009 
 700 
Note: *= variable non-normal distributed; PANSS: Positive and negative Syndrome scale; SANS: The Scale for 
the Assessment of Negative Symptoms; SAPS: The Scale for the Assessment of Positive Symptoms.  PANSS 0-6 
scale was used. Twelve patients were prescribed typical antipsychotic drugs at some stage of their illness 
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Table 3. Uncorrected means (SD) in mm3 for each subcortical structure at baseline and follow-up, and results of statistical comparisons. 
 
 
 
 
 
 
 
 SCHIZOPHRENIA 
(n=33) 
HEALTHY CONTROL 
(n =31) 
GLM 
Baseline 
SCHIZOPHRENIA 
(N=33) 
HEALTHY CONTROL 
(N=31) 
GLM 
Follow-Up 
GLM 
Group*Time* 
Structure 
Mean Vol. Diff. 
Over time (mm3) 
[95% C.I] 
% Volume Difference Over Time 
 (SD) 
STRUCTURES BASELINE BASELINE 
F (8,52) = 1.79, 
p= 0.101 
FOLLOW-UP FOLLOW-UP 
F (8,52) = 3.11; 
p= 0.006 
F (7,41) = 52.54; 
p> 0.001 
 
TRS 
 
HC TRS 
compare
d to HC 
   p   p p     
 Means ± SD Means ± SD  Means ± SD Means ± SD       
Lateral 
Ventricle 
16647.05 ± 9189.84 15272.53 ± 8836.20 0.128 18750.23 ± 9524.54 15413.12 ± 8927.10 0.013 > 0.001 1962.58 [1351.80, 
2573.36] 
14.96  
(11.63) 
1.01  
(3.58) 
13.95  
(11.34) 
Thalamus 17443.74 ± 2078.97 17995.40 ± 2234.72 0.111 16883.71 ± 2065.36 18023.49 ± 2262.84 0.002 > 0.001 -588.13 [-774.19, -
402.06] 
-3.21  
(2.63) 
0.15  
(0.15) 
-3.36  
(3.22) 
Hippocampus 8832.06 ± 773.80 9226.80 ± 830.35 0.027 8596.37 ± 773.36 9226.94 ± 846.99 0.001 > 0.001 -235.83 [-359.41, -
112.26] 
-2.63  
(3.51) 
0.00  
(1.60) 
-2.63  
(3.63) 
Caudate 8456.97 ± 1194.26 8193.08 ± 1204.06 0.189 8052.13 ± 1174.16 8190.45 ± 1200.68 0.597 > 0.001 -402.21 [-501.83, -
302.59] 
-4.83  
(2.49) 
-0.03  
(2.38) 
-4.80  
(3.63) 
Putamen 12781.62 ± 1790.28 12459.92 ± 1761.53 0.388 11993.99 ± 1610.45 12457.48 ± 1798.72 0.073 > 0.001 -785.20 [-947.18, -
623.22] 
-6.07  
(2.50) 
-0.03  
(2.18) 
-6.04  
(3.78) 
Pallidus 4200.93 ± 669.20 3964.46 ± 706.62 0.088 4116.39 ± 612.12 3951.75 ± 704.01 0.243 0.282 -71.83 [-166.04, 
22.39] 
-1.74  
(4.94) 
-0.27  
(2.98) 
-1.47  
(5.34) 
Amygdala 3210.78 ± 339.72 3295.14 ± 426.97 0.428 3141.08 ± 364.80 3265.88 ± 410.05 0.213 0.364 -40.45 [ -114.05, 
33.15] 
-2.16  
(4.88) 
-0.77  
(4.03) 
-1.39  
(5.28) 
Nucleus 
Accumbens 
1188.58 ± 199.04 1198.76 ± 213.56 0.518 1145.21 ± 198.17 1194.95 ± 220.84 0.169 0.060 -39.57 [-74.71, -
4.43] 
-3.50  
(6.24) 
-0.32  
(5.02) 
-3.18  
(7.60) 
Note: the table shows the difference between treatment-resistant schizophrenia patient and healthy control groups on subcortical structures at baseline, follow-up and over time. Post-hoc analyses 
corrected for multiple comparisons (Bonferroni, α= 0.006). Legend: GLM= generalized linear model. C.I = confidence interval; % Vol. Diff. = percentage volume difference; calculated as follows: 100 × 
[(volume at follow-up − volume at baseline)/ volume at baseline], Negative value indicates a % volume decrease over time. TRS= treatment resistant-schizophrenia patients; HC= healthy controls; Bold = 
significant values. 
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Supplementary Data. 
Supplementary Table 1. Uncorrected means (SD) in mm3 for each subcortical structure at baseline and results of statistical comparisons  
 
 
 SCHIZOPHRENIA 
(n=39) 
HEALTHY CONTROL 
(n=40) 
GLM 
Baseline 
Effect size 
Cohen’s d 
STRUCTURES BASELINE BASELINE 
F (8,66) = 1.83, 
p= 0.088 
 
   p  
 Means ± SD Means ± SD   
Lateral Ventricle  16645.83 ± 9038.13  14397.65 ± 8612.52 0.023 0.5 
Thalamus  17375.83 ± 2130.64  17553.04 ± 2238.17  0.112 0.3 
Hippocampus 8852.54 ± 829.88 9134.66 ± 760.41  0.022 0.5 
Caudate 8409.65 ± 1151.67 8044.83 ± 1177.15 0.188 0.3 
Putamen 12630.16 ± 1746.00 12044.24 ± 1801.58  0.350 0.2 
Pallidus 4138.89 ± 659.62 3817.94 ± 708.69  0.119 0.1 
Amygdala  3202.95 ± 360.02  3252.12 ± 393.17 0.399 0.1 
Nucleus 
Accumbens 
1189.09 ± 186.98  1182.88 ± 219.69 0.456 0.1 
Note: the table shows the difference between treatment-resistant schizophrenia patient and healthy control groups 
(Whole initial recruited sample) on subcortical structures at baseline. Cohen’s d was calculated from the F-value of 
Analyses of Covariance and therefore age, gender and ICV were included. 
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Supplementary Table 2. Correlations between neuroanatomical change and clinical variables change in patients 
 
   
 
 
 
 
 
 
 
 
 
 PANSS Negative 
 
 PANSS Positive  PANSS General  PANSS Total  SAPS  SANS  GAF 
                     
STRUCTURES r p  r p  r p  r p  r p  r p  r p 
Lateral Ventricle -0.08 
 
0.692 
 
 0.22 
 
0.243 
 
 0.08 
 
0.692 
 
 0.08 
 
0.686  -0.03 
 
0.879 
 
 -0.03 
 
0.891 
 
 0.03 
 
0.895 
 
Thalamus 0.32 0.086  0.34 0.063  0.39 0.034  0.42 0.021  0.19 0.320  0.36 0.049  -0.32 0.088 
Caudate 0.19 0.328  0.21 0.275  -0.00 0.996  0.13 0.491  0.04 0.823  0.23 0.218  -0.14 0.467 
Putamen 0.31 0.097  0.34 0.067  0.34 0.066  0.39 0.033  *0.39 0.035  0.40 0.027  -0.36 0.052 
Hippocampus -0.16 0.411 
 
 -0.02 0.902 
 
 0.03 0.874 
 
 -0.05 0.795 
 
 -0.08 0.676 
 
 0.03 
 
0.877 
 
 0.00 
 
0.988 
 
Note: PANSS: Positive and Negative Syndrome Scale; SANS: The Scale for the Assessment of Negative Symptoms; SAPS: The Scale for the Assessment of Positive Symptoms. In the correlations 
(Follow-up - Baseline)/Baseline×100) was used to express the volumetric change in subcortical structures and (Follow-up - Baseline) was used to express change in the clinical variables. Correlations 
controlled for age, sex and ICV. * After removing 1 outlier this correlation lost significance (r=0.31; p= 0.102). 
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p<0.001
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p<0.001
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Supplementary Figure 1.  
 
 
